Eight-residue Aβ peptides inhibit the aggregation and enzymatic activity of Aβ42

Regulatory Peptides

Volumn 120, Issue 1-3, 2004, Pages 227-236

  Matsunaga, Yoichi ^a   Fujii, Akihiro ^b   Awasthi, Aradhana ^a   Yokotani, Junichi ^b   Takakura, Tadakazu ^b   Yamada, Tatsuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

A ; AD; Alzheimer's disease; amyloid beta protein; EDTA; ELISA; enzyme linked immunosorbent assay; GdnHCl; guadinine hydrochloride; Guadinine hydrochloride; Metal ions; Proteinase inhibitor; Serine like proteinase activity

Indexed keywords

AMINO ACID; AMYLOID BETA PROTEIN[1-42]; CASEIN; GLUTAMIC ACID; HISTIDINE; PEPTIDE DERIVATIVE; SERINE; SERINE PROTEINASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); COPPER; PEPTIDE FRAGMENT; ZINC;

ACIDITY; AMINO ACID SUBSTITUTION; ARTICLE; CHEMICAL MODIFICATION; ENZYME ACTIVITY; GLIA CELL; HUMAN; HUMAN CELL; PH; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEGRADATION; ACIDOSIS; ALZHEIMER DISEASE; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; GLIA; METABOLISM; PATHOLOGY; SENILE PLAQUE;

ACIDOSIS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; COPPER; HUMANS; NEUROGLIA; PEPTIDE FRAGMENTS; SENILE PLAQUES; ZINC;

EID: 2642557773     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2004.03.013     Document Type: Article

References (45)

1. Katzman R., Saitoh T. Advances in Alzheimer's disease. FASEB J. 5:1991;278-286
2. Barrow C.J., Yasuda A., Kenny P.T.M., Zagorski M.G. Solution conformations and aggregational properties of synthetic amyloid β-peptides of Alzheimer's disease: analysis of circular dichroism spectra. J. Mol. Biol. 225:1992;1075-1093
3. Golabek A.A., Soto C., Vogel T., Wisniewski T. The interaction between apolipoprotein E and Alzheimer's amyloid β-peptide is dependent on β-peptide conformation. J. Biol. Chem. 271:1996;10602-10606
4. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., et al. Diffusible nonfibrillar ligands derived from Abeta 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 95:1998;6448-6453
5. Roher A.E., Chaney M.P., Kuo Y., Webster S.D., Stine W.B., Haverkamp L.J., et al. Morphology and toxicity of Aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem. 271:1996;20631-20635
6. Crawford F., Soto C., Suo Z., Fang C., Parker T., Sawar A., et al. Alzheimer's beta-amyloid vasoactivity: identification of a novel beta-amyloid conformational intermediate. FEBS Lett. 436:1998;445-448
7. Elbaum D., Brzyska M., Bacia A., Alkon D.L. Implication of novel biochemical property of β-amyloid. Biochem. Biophys.Res. Commun. 267:2000;733-738
8. Kelly J.W. The alternative conformations of amyloidogenic proteins and their multistep assembly pathways. Curr. Opin. Struct. Biol. 8:1998;101-106
9. Kirkitadze M.D., Condron M.M., Teplow D.B. Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis. J. Mol. Biol. 312:2001;1103-1119
10. Barrick C.D., Baldwin R.L. The molten globule intermediate of apomyoglobin and the process of protein folding. Protein Sci. 2:1993;869-876
11. Kuwajima K. The molten globule state as a clue for understanding the folding and cooperativity of globular-protein structure. Proteins. 6:1989;87-103
12. Matsunaga Y., Saito N., Fujii A., Yokotani J., Takakura T., Nishimura T., et al. A pH-dependent conformational transition of Aβ peptide and physicochemical properties of the conformers in the glial cell. Biochem. J. 361:2002;547-556
13. Jarrett J.T., Berger E.P., Lansbury P.T. Jr. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 32:1993;4693-4697
14. Burdick D., Soreghan B., Kwon M., Kosmoski J., Knauer M., Henschen A., et al. Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs. J. Biol. Chem. 267:1992;546-554
15. Dill K.A. Dominant forces in protein folding. Biochemistry. 29:1990;7133-7155
16. Wouters M.A., Curmi P.M.G. An analysis of side chain interactions and pair correlations within antiparallel beta-sheets: the differences between backbone hydrogen-bonded and non-hydrogen bonded residue pairs. Proteins. 22:1995;119-131
17. Nordstedt C., Naslund J., Tjernberg L.O., Karlstrom A.R., Thyberg J., Terenius L. The Alzheimer Aβ peptide develops protease resistance in association with its polymerization into fibrils. J. Biol. Chem. 269:1994;30773-30776
18. Abraham C.R., Selokoe D.J., Potter H. Immunochemical identification of the serine protease inhibitor a1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell. 52:1988;487-501
19. Janciauskiene S., Rubin H., Lukacs C.M., Wright H.T. Alzheimer's peptide Aβ1-42 binds to two β-sheets of a1-antichymotrypsin and transforms it from inhibitor to substrate. J. Biol. Chem. 273:1998;28360-28364
20. Hinds T.R., Kukull W.A., VanBelie G., Schellenberg G.D., Villacres E.C., Larson E.B. Relationship between serum alpha-1-antichymotripsin and Alzheimer's disease. Neurobiol. Aging. 15:1994;21-27
21. Barrett A.J., Salvesen G. Proteinase inhibitors. 1986;1-661 Elsevier, Amsterdam
22. Pasternak J.M., Abraham C.R., VanDyke B., Potter H., Younkin S.G. Astrocytes in Alzheimer's disease gray matter express a1-antichymotrypsin mRNA. Am. J. Pathol. 135:1989;827-834
23. Schubert D. Serpins inhibit the toxicity of amyloid peptides. Eur. J. Neurosci. 9:1997;770-777
24. Lundlad R.L., Noyes C.M. Chemical Reagents for Protein Modification. vol. 1:1988;105-126 CRC Press, Boca Raton, FL
25. Badet-Denisot M.A., Bedet B. Chemical modification of glucosamine-6 phosphate synthase by diethyl pyrocarbonate: evidence of histidine requirement for enzymatic activity. Arch. Biochem. Biophys. 292:1992;475-478
26. Hagihara Y., Aimoto S., Fink A.L., Goto Y. Guanidine hydrochloride induced folding of proteins. J. Mol. Biol. 231:1993;180-184
27. Snyder S.W. Amyloid-β aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain length. Biophys. J. 67:1994;1216-1228
28. El-agnaf O.M.A., Guthrie D.J.S., Walsh D.M., Irvine B. The influence of the central region containing residue 19-25 on the aggregation properties and secondary structure of Alzheimer's β-amyloid peptide. Eur. J. Biochem. 256:1998;560-569
29. Hilbich C., Kisters W.B., Reed J., Masters C.L., Beyreuther K. Aggregation and secondary structure of amyloid βA4 protein of Alzheimer's disease. J. Mol. Biol. 218:1991;149-163
30. Hilbich C., Kisters W.B., Reed J., Masters C.L., Beyreuther K. Substitutions of hydrophobic amino acids reduce the amyloidgenicity of Alzheimer's disease βA4 peptides. J. Mol. Biol. 228:1992;460-473
31. Tjernberg L.O., Naslund J., Lindqvist F., Johansson J., Karlstrom A.R., Thyberg J., et al. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 271:1996;218-221
32. Soto C., Sigurdsson E.M., Morelli L., Kumar R.A., Castano E.M., Frangione B. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nat. Med. 4:1998;822-826
33. Sigurdsson E.M., Permanne B., Soto C., Wisniewski T., Frangione B. In vivo reversal of amyloid-β lesions in rat brain. J. Neuropathol. Exp. Neurol. 59:2000;11-17
34. Miyazaki K., Hasegawa M., Funahashi K., Umeda M. A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor. Nature. 362:1993;839-841
35. Hamazaki H. Cathepsin D is involved in the clearance of Alzheimer's β-amyloid protein. FEBS Lett. 396:1996;139-142
36. McDermott J.R., Gibson A.M. Degradation of Alzheimer's β-amyloid protein by human cathepsin D. NeuroReport. 7:1996;2163-2166
37. McDermott J.R., Gibson A.M. Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degradating enzyme. Neurochem. Res. 22:1997;49-56
38. Shao H., Jao S., Ma K., Zagorski M.G. Solution structures of micelle-bound amyloid β-(1-40) and β-(1-42) peptides of Alzheimer's disease. J. Mol. Biol. 285:1999;755-773
39. Lee J.P., Stimson E.R., Ghilardi J.R., Mantyh P.W., Lu Y.A., Felix A.M., et al. 1H NMR of Aβ amyloid peptide congeners in water solution: conformational changes correlate with plaque competence. Biochemistry. 34:1995;5191-5200
40. Halverson K., Fraser P.E., Kirschner D.A., Lansbury P.T. Jr. Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic β-protein fragments. Biochemistry. 29:1990;2639-2644
41. Pike C., Burdick D., Walencewicz A.J., Glabe C.G., Cotman C.W. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13:1993;1676-1687
42. Levy E., Carman M.D., Fernandez M.I.J., Power M.D., Lieberburg I., Van Duinen S.G., et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science. 248:1990;1124-1126
43. Wisniewski T., Ghiso J., Frangione B. Peptides homologous to the amyloid protein of Alzheimer's disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation. Biochem. Biophys. Res. Commun. 179:1991;1247-1254
44. Clements A., Walsh D.M., Williams C.H., Allsop D. Effects of the mutations Glu22 to Gln and Ala21 to Gly on the aggregation of a synthetic fragment of the Alzheimer's amyloid β/A4 peptide. Neurosci. lett. 161:1993;17-20
45. Murakami K., Irie K., Morimoto A., Ohigashi H., Shindo M., Nagao M., et al. Synthesis, aggregation, neurotoxicity and secondary structure of various Aβ1-42 mutants of familial Alzheimer's disease at positions 21-23. Biochem. Biophys. Res. Commun. 294:2002;5-10